Chronic Lymphocytic Leukemia

Omar Alkharabsheh, MD, discusses remaining challenges in high-risk chronic lymphocytic leukemia.

Jacqueline Claudia Barrientos, MD, MS, discusses treatment options for patients with chronic lymphocytic leukemia who harbor TP53 mutations or 17p deletions.

Omar Alkharabsheh, MD, discusses emerging treatment options in chronic lymphocytic leukemia.

Patient enrollment has commenced for the randomized phase 3 ULTRA-V trial, which will evaluate the efficacy of a time-limited combination of umbralisib plus ublituximab and venetoclax vs continuous umbralisib/ublituximab in patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia.

Jacqueline Claudia Barrientos, MD, MS, discusses factors to consider when selecting between BCL-2 inhibitors and BTK inhibitors in chronic lymphocytic leukemia.

Zanubrutinib demonstrated noninferiority in objective response rates and a trend toward improved progression-free survival when compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Mazyar Shadman, MD, discusses the emergence of third-generation BTK inhibitors in chronic lymphocytic leukemia.

Jacqueline Claudia Barrientos, MD, MS, discusses treatment considerations for patients with chronic lymphocytic leukemia.

Jacqueline Claudia Barrientos, MD, MS, discusses the shift away from chemoimmunotherapy in chronic lymphocytic leukemia.

Kerry A. Rogers, MD, discusses the safety profile of the combination of ianalumab plus ibrutinib, in patients with chronic lymphocytic leukemia.

Kerry A. Rogers, MD, discusses the next steps with the triplet combination of obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia.

Paul M. Barr, MD, discusses the next steps with the combination of umbralisib, ublituximab, and venetoclax in chronic lymphocytic leukemia.

Pirtobrutinib showcased encouraging efficacy with an acceptable safety profile in patients with chronic lymphocytic leukemia or small lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia who previously received a BTK inhibitor.

Paul M. Barr, MD, discusses the safety profile of umbralisib plus ublituximab and venetoclax in chronic lymphocytic leukemia.

Mazyar Shadman, MD, discusses considerations for BTK inhibitors in the treatment of patients with chronic lymphocytic leukemia.

R. Gregory Bociek, MD, discusses the clinical uncertainty of minimal residual disease negativity in chronic lymphocytic leukemia.

Mazyar Shadman, MD, discusses continuous vs time-limited treatments for patients with chronic lymphocytic leukemia.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of single-agent duvelisib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia following at least 2 prior therapies, and follicular lymphoma that is refractory to at least 2 prior systemic treatments.

The rolling submission of a biologics license application to support the approval of ublituximab plus umbralisib as a treatment for patients with chronic lymphocytic leukemia has been completed.

Monica D. Mead, MD, discusses the role of BTK inhibition after venetoclax in relapsed/refractory chronic lymphocytic leukemia.

Seema A. Bhat, MD, discusses updates from key studies and highlighted the promise of novel PI3K inhibitors in chronic lymphocytic leukemia.

R. Gregory Bociek, MD, discusses the role of minimal residual disease in patients with chronic lymphocytic leukemia.

Monica D. Mead, MD, discusses ongoing research efforts to overcome BTK inhibitor resistance in patients with chronic lymphocytic leukemia.

Ibrutinib as a frontline treatment led to sustained efficacy and impressive 4-year progression-free and overall survival rates in patients with chronic lymphocytic leukemia who have TP53 aberrations.

Monica D. Mead, MD, discusses the utility of venetoclax in combination with rituximab in the second-line setting for patients with chronic lymphocytic leukemia.